Pibrentasvir

Category: pharmacological

Aliases: Component of Mavyret

Pharmacological Mechanism

Pan-genotypic HCV NS5A inhibitor — blocks viral RNA replication and assembly. Co-formulated with glecaprevir as Mavyret. >97% sustained viral response across HCV genotypes 1–6 in 8-week treatment-naive regimens.

Half-Life (t½)

PO: 23h

Dosing Guidelines

• PO: Typical 120 mg (Range: 120–120 mg)

Target Organ Systems

• immune-hematologic

Pathways It Modulates

• HCV NS3/4A / NS5A / NS5B replication targets (inhibitor) — NS5A

Chemical Identifiers

• PubChem CID: 58031952
• Formula: C57H65F5N10O8
• Molecular weight: 1113.2 g/mol
• InChIKey: VJYSBPDEJWLKKJ-NLIMODCCSA-N
• SMILES: C[C@H]([C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C(=C3)F)[C@H]4CC[C@@H](N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)NC(=O)OC)OC

References

• PMID 28688001